526 related articles for article (PubMed ID: 17785620)
1. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
2. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
Burashnikov A; Belardinelli L; Antzelevitch C
J Pharmacol Exp Ther; 2012 Jan; 340(1):161-8. PubMed ID: 22005044
[TBL] [Abstract][Full Text] [Related]
3. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
[TBL] [Abstract][Full Text] [Related]
5. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.
Sicouri S; Burashnikov A; Belardinelli L; Antzelevitch C
Circ Arrhythm Electrophysiol; 2010 Feb; 3(1):88-95. PubMed ID: 19952329
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
Burashnikov A; Belardinelli L; Antzelevitch C
Heart Rhythm; 2015 Apr; 12(4):836-44. PubMed ID: 25546810
[TBL] [Abstract][Full Text] [Related]
7. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
Burashnikov A; Pourrier M; Gibson JK; Lynch JJ; Antzelevitch C
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):400-8. PubMed ID: 22322366
[TBL] [Abstract][Full Text] [Related]
8. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
[TBL] [Abstract][Full Text] [Related]
9. AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.
Burashnikov A; Zygmunt AC; Di Diego JM; Linhardt G; Carlsson L; Antzelevitch C
J Cardiovasc Pharmacol; 2010 Jul; 56(1):80-90. PubMed ID: 20386458
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model.
Nesterenko VV; Zygmunt AC; Rajamani S; Belardinelli L; Antzelevitch C
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1615-24. PubMed ID: 21821780
[TBL] [Abstract][Full Text] [Related]
11. Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.
Burashnikov A; Petroski A; Hu D; Barajas-Martinez H; Antzelevitch C
Heart Rhythm; 2012 Jan; 9(1):125-31. PubMed ID: 21884675
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
Antzelevitch C; Belardinelli L; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Thomas G
Circulation; 2004 Aug; 110(8):904-10. PubMed ID: 15302796
[TBL] [Abstract][Full Text] [Related]
13. Atrial-ventricular differences in rabbit cardiac voltage-gated Na
Caves RE; Cheng H; Choisy SC; Gadeberg HC; Bryant SM; Hancox JC; James AF
Heart Rhythm; 2017 Nov; 14(11):1657-1664. PubMed ID: 28610990
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
Burashnikov A; Sicouri S; Di Diego JM; Belardinelli L; Antzelevitch C
J Am Coll Cardiol; 2010 Oct; 56(15):1216-24. PubMed ID: 20883928
[TBL] [Abstract][Full Text] [Related]
15. Larger late sodium current density as well as greater sensitivities to ATX II and ranolazine in rabbit left atrial than left ventricular myocytes.
Luo A; Ma J; Song Y; Qian C; Wu Y; Zhang P; Wang L; Fu C; Cao Z; Shryock JC
Am J Physiol Heart Circ Physiol; 2014 Feb; 306(3):H455-61. PubMed ID: 24322614
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
Antzelevitch C; Burashnikov A; Sicouri S; Belardinelli L
Heart Rhythm; 2011 Aug; 8(8):1281-90. PubMed ID: 21421082
[TBL] [Abstract][Full Text] [Related]
17. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes.
Song Y; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2031-9. PubMed ID: 18310511
[TBL] [Abstract][Full Text] [Related]
18. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A
Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block.
Zygmunt AC; Nesterenko VV; Rajamani S; Hu D; Barajas-Martinez H; Belardinelli L; Antzelevitch C
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1606-14. PubMed ID: 21821778
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
